Aim: α7nAChR agonist GTS-21 is potentially a new treatment for type 2 diabetes (T2D)
owing to its ability to stimulate GLP-1 secretion. This study sought to establish if GTS-21 …

Incorporation of the α5 nicotinic acetylcholine receptor (nAChR) subunit can greatly
influence nAChR function without altering receptor number. Although few animal studies …

Previous studies have suggested that treatment with antagonists or partial agonists of
nicotinic acetylcholine receptors containing the β2-subunit (β2* nAChRs) results in …

Background: Because of their implications in several pathological conditions, α4β2* nicotinic
acetylcholine receptors (nAChRs) are potential targets for the treatment of nicotine …

Evidence suggests that there is an association between polymorphisms in the α5 nicotinic
acetylcholine receptor (nAChR) subunit and risk of developing alcohol dependence in …

Neuronal acetylcholine nicotinic receptors (nAChR) are composed of 12 subunits (α2‐10, β2‐
4), of which α3, α5, α7, β2 and β4 subunits are known to exist in the autonomic nervous …

It is considered that activation of nicotinic α7 receptors (α7 nAChR) is useful for the treatment
of cognitive disturbances in schizophrenia and Alzheimer's disease. Recently, selective α7 …

Background and Purpose Disruptions of executive function, including attentional deficits, are
a hallmark of a number of diseases. ACh in the prefrontal cortex regulates attentive …

Background Alpha7 and α4β2 nicotinic acetylcholine receptor (nAChR) agonists have been
shown to improve cognition in various animal models of cognitive impairment and are of …

In this paper, we report on the pharmacological and functional profile of SSR180711 (1, 4-
Diazabicyclo [3.2. 2] nonane-4-carboxylic acid, 4-bromophenyl ester), a new selective α7 …